# A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)

> **NCT00979459** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 12 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** MK-1006 DFC
- **DRUG:** MK-1006 FCT

## Key facts

- **NCT ID:** NCT00979459
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2009-11
- **Final completion:** 2009-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2016-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00979459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00979459, "A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00979459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*